MK-3207 HCl 化学構造
分子量: 594.05

品質と確認

Quality Control & MSDS

製品情報

  • Compare CGRP Receptor Inhibitors
    CGRP Receptor阻害剤を比較

製品の説明

生物活性

情報 MK-3207 HClは、0.12nMのIC50によるカルシトニン遺伝子関連ペプチド(CGRP)受容体拮抗剤です。
目標 CGRP
IC50 0.12 nM [1]
In vitro試験 MK 3207 exhibits significantly higher affinity for both native and recombinant human CGRP receptor, as well as rhesus monkey CGRP receptor with Ki of 24 pM, ~24 pM and 22 pM, respectively, as compared to CGRP receptors from other species, including canine and rodent (Ki values of ~10 nM). Although has affinity for AMY1 (CTR/RAMP1) receptor with a Ki value of 0.75 nM, MK 3207 displays marked selectivity for human CGRP receptor versus related human AM1 (CLR/RAMP2) receptor, AM2 (CLR/RAMP3) receptor, AMY3 (CTR/RAMP3) receptor, and CTR with Ki values of 16.5 μM, 0.156 μM, 0.128 μM and 1.9 μM, respectively. MK 3207 potently inhibits human α-CGRP-induced cAMP production in HEK293 cells stably expressing human CLR/RAMP1 with an IC50 of 0.12 nM, and maintains similar potency in the presence of 50% human serum with an IC50 of 0.17 nM, indicating that the activity of MK 3207 would not be dramatically affected by plasma protein binding in vivo. MK 3207 exhibits approximately 65-fold more potent in the human serum-shifted in vitro functional assay than telcagepant with an IC50 of 10.9 nM. [1]
In vivo試験 Administration of MK 3207 produces a concentration-dependent inhibition of capsaicin-induced dermal vasodilation in rhesus monkeys, blocking the blood flow increase with an EC50 of 0.8 nM and an EC90 of 7 nM, respectively. MK 3207 displays approximately 100-fold more potent in the rhesus monkey CIDV assay versus telcagepant with an EC90 of 994 nM. [1]
臨床試験 A Phase II study to demonstrate the effectiveness and appropriate dosage level of MK 3207 in the treatment of acute migraine has been completed.
特集 The most potent orally active CGRP receptor antagonist described to date.

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

In Vitro Functional Study HEK293 cells stably expressing the human CGRP receptor are preincubated with various concentrations of MK 3207 in the presence or absence of 50% human serum for 30 minutes at 37 °C. Isobutyl-methylxanthine (300 μM) is added to the cells, and then they are incubated for 30 minutes at 37 °C followed by stimulation with 0.3 nM α-CGRP for 5 minutes at 37 °C. After agonist stimulation cells are washed with PBS and the intracellular cAMP concentration is measured using the cAMP SPA Biotrak direct screening assay. Dose-response curve is plotted, and IC50 value is determined.

動物実験: [1]

動物モデル Adult rhesus monkeys (either sex) with capsaicin-induced dermal vasodilation
製剤 Dissolved in DMSO
投薬量 ~123.1 μg/kg
管理 Intravenous bolus followed by 25 minutes continuous intravenous infusion
Solubility 1% DMSO/30% polyethylene glycol/1% Tween 80, 30 mg/mL
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesBaboonDogMonkeyRabbitGuinea pigRatHamsterMouse
Weight (kg)121031.80.40.150.080.02
Body Surface Area (m2)0.60.50.240.150.050.0250.020.007
Km factor202012128653
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download MK-3207 HCl SDF
分子量 594.05
化学式

C31H29F2N5O3.HCl

CAS No. 957116-20-0
保管 2年-20℃
6月-80℃in DMSO
別名
溶解度 (25°C) * In vitro DMSO 119 mg/mL (200 mM)
5 mg/mL (8 mM)
エタノール 119 mg/mL (200 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 6,9-Diazaspiro[4.5]decane-9-acetamide, 8-(3,5-difluorophenyl)-10-oxo-N-[(2R)-1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl]-, hydrochloride

研究分野

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related CGRP受容体 阻害剤

  • Purmorphamine

    Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM and also is an inducer of osteoblast differentiation with EC50 of 1 μM.

  • Bosentan

    Bosentan is an endothelin (ET) receptor antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.

  • PF-543

    PF-543 is a cell-permeant, selective sphingosine kinase 1 (Sphk1) inhibitor with Ki of 3.6 nM, >100-fold selective over SphK2.

  • BMS-833923

    BMS-833923 is an orally bioavailable Smoothened antagonist. Phase 2.

  • Vismodegib (GDC-0449)

    Vismodegib (GDC-0449)は、強力で、新しくて、特定のハリネズミ経路阻害剤で、 IC50 が 3 nMになる。

  • Cyclopamine

    Cyclopamineは、スムーズにされる(SMO)ものの経路敵対者に合図している特定のハリネズミ(Hh)で、 IC50 が 46 nM。

  • Forskolin

    Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC), commonly used to raise levels of cAMP in the study and research of cell physiology.

  • Fingolimod (FTY720) HCl

    Fingolimod (FTY720) HCl(フィンゴリモド、Gilenya)は、0.033nMのIC50によるスフィンゴシン1-リン酸(S1P)受容体拮抗剤です。

  • Plerixafor 8HCl (AMD3100 8HCl)

    Plerixafor 8HCl (AMD3100 8HCl) は、CXCR4ケモカイン受容体拮抗剤で、 CXCR4 、 CXCL12媒介走化性に作用すると、 IC50 が それぞれ44 nM と 5.7 nMになる。

最近見られたアイテム

Tags: MK-3207 HClを買う | MK-3207 HCl供給者 | MK-3207 HClを購入する | MK-3207 HCl費用 | MK-3207 HCl生産者 | オーダーMK-3207 HCl | MK-3207 HCl代理店
お問い合わせ